Free ACG Clinical Guidelines Questions and Answers — Questions and Answers
Question 1: According to ACG guidelines, which of the following is the recommended first-line treatment for Helicobacter pylori infection in a patient with no history of macrolide exposure?
- Bismuth quadruple therapy
- Clarithromycin triple therapy (Correct answer)
- Proton pump inhibitor (PPI) monotherapy
- Amoxicillin monotherapy
Correct answer: Clarithromycin triple therapy
According to ACG guidelines, clarithromycin triple therapy (PPI, clarithromycin, and amoxicillin or metronidazole) is recommended as a first-line treatment for H. pylori infection in patients with no prior macrolide exposure. This regimen is effective in eradicating the bacteria when clarithromycin resistance rates are low. It provides a balanced approach to treatment by combining acid suppression with two antibiotics.
Question 2: For patients with Barrett’s esophagus without dysplasia, what is the recommended surveillance interval according to ACG guidelines?
- Every 3 months
- Every 6 months
- Every 3-5 years (Correct answer)
- Every 10 years
Correct answer: Every 3-5 years
ACG guidelines recommend endoscopic surveillance with biopsies every 3-5 years for patients diagnosed with Barrett's esophagus without dysplasia. This interval is considered appropriate for monitoring the condition and detecting any progression, such as the development of dysplasia, while avoiding overly frequent and unnecessary procedures. Regular surveillance helps manage the risk of esophageal adenocarcinoma.
Question 3: According to ACG guidelines, what is the recommended first-line therapy for inducing remission in patients with moderate to severe Crohn's disease?
- 5-Aminosalicylates (5-ASA)
- Antibiotics (e.g., ciprofloxacin)
- Corticosteroids
- Anti-TNF agents (e.g., infliximab) (Correct answer)
Correct answer: Anti-TNF agents (e.g., infliximab)
For patients with moderate to severe Crohn's disease, ACG guidelines recommend anti-TNF agents (e.g., infliximab) as the first-line therapy for inducing remission. These biologic medications target specific inflammatory pathways, offering potent and sustained control of the disease. They are more effective than traditional therapies like 5-ASAs or corticosteroids for achieving deep remission in more severe cases.
Question 4: According to ACG guidelines, which of the following is the preferred test for initial evaluation of suspected celiac disease?
- Anti-tissue transglutaminase (anti-tTG) IgA antibodies (Correct answer)
- HLA-DQ2/DQ8 genetic testing
- Endoscopic biopsy of the small intestine
- Anti-gliadin IgG antibodies
Correct answer: Anti-tissue transglutaminase (anti-tTG) IgA antibodies
The anti-tissue transglutaminase (anti-tTG) IgA antibody test is the preferred initial screening test for suspected celiac disease, according to ACG guidelines. This test has high sensitivity and specificity, making it a reliable first step in identifying individuals who may have celiac disease. A positive result typically warrants further confirmatory testing, such as an endoscopic biopsy of the small intestine.
Question 5: According to ACG guidelines, which of the following screening intervals is recommended for patients with average risk for colorectal cancer, beginning at age 45?
- Colonoscopy every 5 years
- Fecal immunochemical test (FIT) annually (Correct answer)
- Double-contrast barium enema every 10 years
- Capsule endoscopy every 2 years
Correct answer: Fecal immunochemical test (FIT) annually
For average-risk individuals beginning at age 45, ACG guidelines recommend several options for colorectal cancer screening. Among the non-invasive methods, the Fecal Immunochemical Test (FIT) is recommended annually. FIT is an effective and convenient test for detecting occult blood in stool, which can be an indicator of polyps or colorectal cancer.
Free ACG Clinical Guidelines Questions and Answers
According to ACG guidelines, which of the following is the recommended first-line treatment for Helicobacter pylori infection in a patient with no history of macrolide exposure?